The DOI matches its Crossref record; 612 of the 626 references it cites were found in a registry or an index.
A comprehensive review of immune checkpoint inhibitors for cancer treatment
Abstract
Immunology-based therapies are emerging as an effective cancer treatment, using the body's immune system to target tumors. Immune checkpoints, which regulate immune responses to prevent tissue damage and autoimmunity, are often exploited by cancer cells to avoid destruction. The discovery of checkpoint proteins like PD-1/PD-L1 and CTLA-4 was pivotal in developing cancer immunotherapy. Immune checkpoint inhibitors (ICIs) have shown great success, with FDA-approved drugs like PD-1 inhibitors (Nivolumab, Pembrolizumab, Cemiplimab), PD-L1 inhibitors (Atezolizumab, Durvalumab, Avelumab), and CTLA-4 inhibitors (Ipilimumab, Tremelimumab), alongside LAG-3 inhibitor Relatlimab. Research continues on new checkpoints like TIM-3, VISTA, B7-H3, BTLA, and TIGIT. Biomarkers like PDL-1 expression, tumor mutation burden, interferon-γ presence, microbiome composition, and extracellular matrix characteristics play a crucial role in predicting responses to immunotherapy with checkpoint inhibitors. Despite their effectiveness, not all patients experience the same level of benefit, and organ-specific immune-related adverse events (irAEs) such as rash or itching, colitis, diarrhea, hyperthyroidism, and hypothyroidism may occur. Given the rapid advancements in this field and the variability in patient outcomes, there is an urgent need for a comprehensive review that consolidates the latest findings on immune checkpoint inhibitors, covering their clinical status, biomarkers, resistance mechanisms, strategies to overcome resistance, and associated adverse effects. This review aims to fill this gap by providing an analysis of the current clinical status of ICIs, emerging biomarkers, mechanisms of resistance, strategies to enhance therapeutic efficacy, and assessment of adverse effects. This review is crucial to furthering our understanding of ICIs and optimizing their application in cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Cited by
The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances
Chen, H., Yang, H., Guo, L., & Sun, Q. (2025) · MedComm · doi:10.1002/mco2.70412 · Cited by 66
Li, J., Peng, J., Wang, J., & Chen, Z. (2025) · Med Research · doi:10.1002/mdr2.70022 · Cited by 62
Han, X., Zhang, J., Li, W., Huang, X., Wang, X., Wang, B., Gao, L., & Chen, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1512509 · Cited by 55
Roussot, N., Kaderbhaï, C., & Ghiringhelli, F. (2025) · Cancers · doi:10.3390/cancers17050906 · Cited by 34
Dendritic cell immunotherapy advances for solid tumors: Vaccination and modulation
Clayton, G., Toffoli, E. C., de Gruijl, T. D., & van Kooyk, Y. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102412 · Cited by 30
The microbiome as a therapeutic co-driver in melanoma immuno-oncology
Bautista, J., Chávez, J. A. V., Larco, D. S. B., Martín-Aguilera, R., & López‐Cortés, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1673880 · Cited by 28
Lanis, M. R., Kim, S., & Schneck, J. P. (2025) · Gels · doi:10.3390/gels11110889 · Cited by 25
Song, Y., Kong, H., Oh, S., & Kim, S. B. (2025) · BMB Reports · doi:10.5483/bmbrep.2024-0193 · Cited by 24
Recent advances in oncolytic virus combined immunotherapy in tumor treatment
Zhou, X., Hu, S., & Wang, X. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101599 · Cited by 24
Immune checkpoint blockade in cancer: current insights and future horizons
Saman, H. T., Makni‐Maalej, K., El-Ella, D. M. A., Al-Tamimi, M. Y., AbuHaweeleh, M. N., Abuhayeh, N., Ismail, M. A., Prabhu, K. S., Fernandes, Q., Jabi, T., et al. (2026) · Discover Oncology · doi:10.1007/s12672-025-04361-7 · Cited by 23
Retrospective analysis of clinical features of pembrolizumab induced psoriasis
Shu, M., Fan, Z., Huang, B., & Wang, C. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01536-5 · Cited by 23
Li, X., Meng, H., Wang, H., Zhang, Y., & Yu, W. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1640073 · Cited by 22
Cancer Immunotherapy—An Overview
Kulkarni, P., Do, D., Shrestha, S., Leach, B., & Salgia, R. (2025) · Cancer treatment and research · doi:10.1007/978-3-031-97242-3_1 · Cited by 21
Gao, P., Li, X., Duan, Z., Wang, Y., Li, Y., Wang, J., Luo, K., & Chen, J. (2025) · MedComm · doi:10.1002/mco2.70274 · Cited by 20
Application of Immune Checkpoint Inhibitors in Cancer
Chen, Z., Song, Z., Den, S., Zhang, W., Han, M., Lan, T., Du, X., Ning, J., Chen, X., Lin, H., et al. (2025) · MedComm · doi:10.1002/mco2.70176 · Cited by 18
Yousefi, M., Gharaie, D., Javan, M. R., & Khosrojerdi, A. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115986 · Cited by 18
Jia, Z., Lu, S., Wang, Z., & Ge, P. (2025) · Oncology Letters · doi:10.3892/ol.2025.15381 · Cited by 17
Colorectal cancer pathogenesis, oncogenic signaling networks and targeted therapeutic advances
Chen, Y., Zhang, J., Ding, Y., Zhu, F., & Chen, Y. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00433-4 · Cited by 17
Cholesterol metabolism: a new checkpoint in cancer immunity
Zhao, L., Zheng, R., Liu, W., Li, X., Liu, H., Yin, H., Zhang, R., & Yang, A. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.11.003 · Cited by 15
Renukadevi, J., Helinto, J. S., & Prena, D. (2025) · Journal of Bio-X Research · doi:10.34133/jbioxresearch.0028 · Cited by 15
Zhang, H., Zhou, Z. L., Wang, J., Wang, S., Ren, J., Zhang, M., & Yang, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1582050 · Cited by 14
Xu, Q., Jiang, Z., Pan, Y., Li, S., Cao, Z., Hua, S., Yang, R., He, Q., Wu, H., Wen, H., et al. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157017 · Cited by 14
Notch signaling in the tumor microenvironment: recent advances and targeted therapeutics
Chen, D., Gu, X., Liu, J., Xu, L., Ye, Z., Gao, P., Li, H., Jiao, H., Liu, P., Li, G., et al. (2026) · Molecular Cancer · doi:10.1186/s12943-025-02555-9 · Cited by 13
Song, D., Zhang, J., Zhou, J., Yuan, X., Tang, L., Sun, K., Shi, Q., Sun, H., & Zhao, W. (2025) · Current Proteomics · doi:10.1016/j.curpro.2025.100060 · Cited by 13
Li, Y., Li, J., Mo, W., & Xu, X. (2025) · Oncology Reports · doi:10.3892/or.2025.8953 · Cited by 12
Stefanou, E., Tsitsinakis, G., Karageorgou, D., & Kole, C. (2025) · Cancers · doi:10.3390/cancers17172838 · Cited by 12
Di, X., Shí, X., Gai, F., & Wang, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1621045 · Cited by 11
Advances in lipid nanoparticles delivering genetic medicines for solid cancers
Yang, F., & Scott, T. A. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102838 · Cited by 11
AI-enhanced synergistic chemo-immunotherapy: From mechanistic insights to clinical translation
Muhammad, S., Li, B., Zhong, W., Siddiqui, H. L., Zhao, Y., & Wang, J. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105064 · Cited by 10
Alshahrani, A., Alsubait, A., Asiri, Z. A., Alghamdi, S. S., Saqyah, S. B., Alqahtani, T., Fitaihi, R. A., Altuwaijri, N., & Jamous, Y. F. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1684896 · Cited by 10
Xu, Y., Shen, H., Shang, D., & Zhu, C. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1665239 · Cited by 10
Topcu, K. S. B., & Çaçan, E. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70586 · Cited by 9
Correlation of CLDN18.2 and Tumor Microenvironment in Gastric Cancer: A Systematic Review
Zarampouka, K., Tsiantas, C., Stavropoulou, M. A., Efthymiadis, K., Theotokis, P., Gargani, S., Vrettou, E., Κoletsa, T., Μanthou, M. E., & Meditskou, S. (2025) · Cancers · doi:10.3390/cancers17132120 · Cited by 9
Kawczak, P., Feszak, I. J., & Bączek, T. (2025) · Cancers · doi:10.3390/cancers17172805 · Cited by 9
Tumor-associated high endothelial venules as therapeutic modulation targets in cancer immunotherapy
Zhang, J.-Y., Piao, Z.-Y., Su, G.-L., Zhang, M.-J., & Sun, Z. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189500 · Cited by 9
Covalent organic frameworks for cancer immunotherapy: mechanisms, applications, and prospects
Zou, Y., Chen, M., Chen, J., Wang, W., & Zheng, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1719005 · Cited by 9
Baldi, S., Alnaggar, M., AL-Mogahed, M., Khalil, K., & Zhan, X. (2025) · The EPMA Journal · doi:10.1007/s13167-025-00403-w · Cited by 8
Medulloblastoma: biology and immunotherapy
Poggi, A. D., Reggiani, F., Azevedo, H. S., Raffaghello, L., & Pereira, R. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1602930 · Cited by 8
Advances in biomarkers of resistance to KRAS mutation-targeted inhibitors
Wang, L., Wei, D., Li, S., & Jiang, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-03569-x · Cited by 8
Yu, C., Zhang, D., Chen, C., Xing, S., Li, P., Zhang, Y., Shang, L., Ma, H., & Zhou, J. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105191 · Cited by 8
The evolving global landscape of first-in-class oncology drug innovation
Mao, X., Wang, Z., Kong, S., Yang, Y., Dreyer, N. A., Ba, Y., Lotze, M. T., Zhan, Q., & Li, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02606-7 · Cited by 8
Tumor-infiltrating lymphocyte expansion protocols for adoptive cell therapy in cancer
Manzano, D. T., Subhi‐Issa, N., Pereiro-Rodríguez, A., Cade, I. G. L., González, M. M., Fernández‐Arquero, M., Segura, P. P., Ujaldón‐Miró, C., Sánchez‐Ramón, S., Ocaña, A., et al. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01112-2 · Cited by 7
Yari, A., Hosseini, S. Y., Asiyabi, S., Hajiahmadi, N., Farahmand, M., & Bamdad, T. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2501926 · Cited by 7
mTOR ‐mediated upregulation of B7 ‐ H3 in MiT / TFE translocation renal cell carcinoma
Li, H., Amaral, A., Vidotto, T., Woo, J., Liu, H. B., Oliveira, L. D., Dairo, O., Feng, K., Shenderov, E., Argani, P., et al. (2025) · The Journal of Pathology · doi:10.1002/path.6490 · Cited by 6
Zhao, H., Yang, F., Yang, J., & Yang, S. (2025) · Cytokine · doi:10.1016/j.cyto.2025.157090 · Cited by 6
Turlej, E., Domaradzka, A., Koksharov, R., & Gizak, A. (2026) · Cancers · doi:10.3390/cancers18030344 · Cited by 6
Inhibition of Skp2 enhances anti-tumor immunity of macrophages by regulating CD47 in gastric cancer
Hu, K., Zhao, L., Miao, P., Qiu, W., Ai, L., Chen, X., Wang, S., Chen, X., & Shi, X. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115262 · Cited by 6
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions
Damiani, D., & Tiribelli, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104571 · Cited by 5
Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies
Tran, H. T. T., Tran, T. M., Le, D. V., Jacobs, J. C., Nguyen, T. M., Trinh, H. L., Vo, B. T., Tran, T. S., & Nguyen, G. H. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01333-5 · Cited by 5
Progress of immune checkpoint inhibitors in gastric cancer
Wan, J.-Y., Zhang, D., Wu, X., Yang, H., & Dong, C. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i8.109613 · Cited by 5
Chan, N. S. L., Cross, C., Prestidge, C. A., Wardill, H. R., Bowen, J. M., & Joyce, P. M. (2026) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2025.2610215 · Cited by 5
Gómez-Preciado, F., Martínez-Valenzuela, L., Antón-Pàmpols, P., Fulladosa, X., Jové, M., Nadal, E., Cruzado, J. M., Torrás, J., & Draibe, J. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031240 · Cited by 5
IGSF11-Mediated Immune Modulation: Unlocking a Novel Pathway in Emerging Cancer Immunotherapies
Srivastava, S., Kartikasari, A. E. R., Telukutla, S. R., Plebanski, M., & Banerjee, D. (2025) · Cancers · doi:10.3390/cancers17162636 · Cited by 5
Chen, T., Li, X., Hong, D., Yin, L., Fang, C., Chen, X., Yang, Z.-X., Zhao, P., Hu, L., Wang, Z., et al. (2025) · Thyroid · doi:10.1177/10507256251372644 · Cited by 5
Manco, L., Proietti, I., Scribano, G., Pirisino, R., Bagni, O., Potenza, C., Pellacani, G., & Filippi, L. (2025) · Applied Sciences · doi:10.3390/app15126453 · Cited by 4
Sun, Y., Liu, D., Liu, Y., & Chi, L. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05106-x · Cited by 4
Puglisi, M. M., May, L., Gardiyehewa, T., & Landry, J. W. (2025) · Cancers · doi:10.3390/cancers17243953 · Cited by 4
Molecular Pathogenesis and Targeted Treatment of Richter Transformation
Maher, N., Karami, A., Matti, B. F., Alwan, A. F., Sayedi, S. M., Moia, R., Gaïdano, G., & Mouhssine, S. (2026) · Biomedicines · doi:10.3390/biomedicines14020347 · Cited by 4
Cao, R., Wei, Q., Yan, S., Gong, C., Bu, L., & Wu, Q. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105415 · Cited by 4
Teschke, R. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1771858 · Cited by 4
Lymphocyte exhaustion in hepatocellular carcinoma: a dynamic evolution across disease stages
Fuster, C., Corominas, J., Marsal, A., Llarch, N., Iserte, G., Sanduzzi‐Zamparelli, M., Forner, A., Ferrer, J., Holguin, V., Morales, A., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1611365 · Cited by 4
Schmidt, F., Wu, K. X., Purwanti, Y. I., Tan, N. Y. Z., Carbajo, D., Bok, K. X., Wilm, A., Fehlings, M., MacLeod, D. T., Nardin, A., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1629802 · Cited by 4
Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Related Myocarditis
Hammer, M., Tysarowski, M., Fuss, C., & Bader, A. S. (2025) · Echocardiography · doi:10.1111/echo.70131 · Cited by 4
Dong, H., Li, S., Peng, Y., Zhang, X., Zheng, J., Xue, C., Zheng, Y., Yu, Y., Lu, X., Hu, Z., et al. (2025) · Oncology Letters · doi:10.3892/ol.2025.15023 · Cited by 4
Dual roles of GM-CSF in breast cancer: Immunomodulation and therapeutic implications
Guo, Y., Hu, Y., Huang, D., Yang, J., Fu, S., Deng, X., Long, J., Wang, J., & Wang, Y. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104804 · Cited by 4
Li, C.-R., Lin, M.-Z., Li, B., Li, H., Chen, Y., Zheng, Z., & Hui, Y.-M. (2025) · Translational Cancer Research · doi:10.21037/tcr-2024-2631 · Cited by 3
García-Vázquez, N., Nada, H., Upadhyay, S., & Gabr, M. T. (2025) · RSC Advances · doi:10.1039/d5ra03914b · Cited by 3
Invisible influencers: the tumor microbiome’s impact on immunotherapy in colorectal cancer (CRC)
Omar, T. M., Al-Hussainy, A. F., Jyothi, S. R., Nayak, P. P., Janney, J. B., Singh, G., Polatova, D., Sameer, H. N., Salih, R. M., Adil, M., et al. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2579656 · Cited by 3
CliCAR: A non-genetic CAR engineering strategy to empower NK cells for targeted cancer immunotherapy
Lim, S. Y., Kim, Y., Han, S., Kim, H., Ha, S.-J., Park, J., Yun, J., Chae, S., Won, Y., & Lim, K. S. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118691 · Cited by 3
Li, H., Wang, Y., 朱建锋, Chen, H., Liu, T., & Ai, L. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013108 · Cited by 3
Jiao, C., Zhang, T., Yang, Y., Zhang, R., Liu, W., & Wang, Y. (2026) · Pain Research and Management · doi:10.1155/prm/7197339 · Cited by 3
Islam, R., Figura, M., Heyer, J., Lieber, S., Huber, M., Loveland, K. L., Schuppe, H., & Fietz, D. (2026) · Andrology · doi:10.1111/andr.70200 · Cited by 3
Current evidence and emerging approaches in immunotherapy for gynecological cancers
Ashonibare, V. J., Hezekiah, O. S., Kukoyi, O. S., Hassan, S. A., Afolabi, O. A., Akhigbe, T. M., & Akhigbe, R. E. (2026) · Discover Oncology · doi:10.1007/s12672-026-04785-9 · Cited by 3
Role of ferroptosis on immunotherapy in breast cancer
Deng, K., & Li, H. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11828-5 · Cited by 3
Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges
Hu, R., Dai, K., Lin, Z., Ye, M., Chen, M., Li, X. D., & Zhang, D. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70375 · Cited by 3
Dai, Y., Yang, W., Sun, Z., Wu, L., Shao, K., & Wu, D. (2026) · Cancer Medicine · doi:10.1002/cam4.71948 · Cited by 3
Role for long term treatment in NMOSD induced by the immune checkpoint inhibitor cemiplimab
Oelbrandt, F., Marignier, R., & Dubois, B. (2025) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2025.109120 · Cited by 3
Shi, Y., Yu, Y., Zhao, J., Huang, L., Wang, Q., Sun, Q., Liu, L., & Sun, C. (2025) · Discover Oncology · doi:10.1007/s12672-025-01812-z · Cited by 2
Feng, Z., Tu, Y., Xu, L., Yi, H., Zhuang, Z., & Liu, B. (2025) · Journal of Thoracic Disease · doi:10.21037/jtd-2024-2099 · Cited by 2
Kang, N., Chen, Q., Guo, Y., Li, H., Zou, B., Cai, T., Li, W., Yu, Y., Luo, Z., Bu, J., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003301 · Cited by 2
Lin, S., & Yu, X. (2025) · Medicine · doi:10.1097/md.0000000000046137 · Cited by 2
Immune-Related Adverse Events of Checkpoint Inhibitors and Human Leukocyte Antigen System: A Review
Kośmider, K., Kozakiewicz, A., Krawczyk, P. A., Kieszko, R., Szklener, K., Skórzewska, M., Wojas‐Krawczyk, K., Kalinka‐Warzocha, E., & Milanowski, J. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s548443 · Cited by 2
Kaźmierczak-Siedlecka, K., Kucharski, R., Stachowska, E., Pelikant‐Małecka, I., Marano, L., Makarewicz, W., Kalinowska, M., Dambrauskas, Z., & Kalinowski, L. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1732712 · Cited by 2
A responder-informed gut microbial consortium enhances anti-PD-1 efficacy in a mouse cancer model
Jeong, U. J., Ali, M., Park, Y. J., You, J. S., & Yoon, S. S. (2026) · Microbiome Research Reports · doi:10.20517/mrr.2025.117 · Cited by 2
The gut microbiota: an emerging therapeutic target for ICI-associated myocarditis
Huang, Z., Mei, X., & Zhou, Y. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1752485 · Cited by 2
Aloliqi, A. A., Alnuqaydan, A. M., Alshebremi, M., Khan, A., & Khan, M. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062528 · Cited by 2
Immunologic Drivers and Restraints in Colitis-Associated Colorectal Cancer
Frascatani, R., Laudisi, F., Stolfi, C., & Monteleone, G. (2026) · Cancers · doi:10.3390/cancers18081230 · Cited by 2
Immunotherapy‐Related Cystitis Induced by Nivolumab for Advanced Gastric Cancer: A Case Report
Arinami, K., Ito, K., Hasegawa, G., Takizawa, Y., Ikeda, Y., Suda, T., Hara, N., & Nishiyama, T. (2026) · Case Reports in Urology · doi:10.1155/criu/4082092 · Cited by 2
Advances in Cancer Immunotherapy for Solid Tumors
Gabizon–Peretz, S., & Kluger, H. M. (2026) · Advanced Science · doi:10.1002/advs.76020 · Cited by 2
Enhancing glioma immunotherapy by disrupting RBP-J-mediated NNMT signaling in tumor microenvironment
Zhang, D., Guan, N., Feng, X., Wang, Y., Zhang, L., Liu, J., & Zhang, S. (2026) · Oncogene · doi:10.1038/s41388-026-03844-3 · Cited by 2
Emerging role of microRNAs as modulators of the tumor immune microenvironment
Frigerio, R., Ortolano, A., Ciliberto, G., Mancini, R., & Fattore, L. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014528 · Cited by 2
Metal-phenolic networks: a promising strategy for cancer immunotherapy
Wang, M., Li, X. G., Xu, Z., Wang, Y., Zheng, Y., Li, A., Chen, L., Zhao, M., Ding, D., & Ji, X. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08610-3 · Cited by 2
Deipenbrock, A., Hofer, L., Wilmes, B. E., Cetin, T., Esposito, I., Weyhe, D., Stegmaier, J., & Teusch, N. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1844781 · Cited by 2
Huang, S., Li, J., Gu, D., Li, Z., Chen, H., & Xiong, W. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1623875 · Cited by 2
Yu, M., Ding, Y., Ji, L., Zhang, Y., Wu, K. K., Zhang, J., Cao, R., Liu, Y., Bian, Y., Shen, X., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1679817 · Cited by 2
Sivaprakasam, T., Nitchaikulvatana, P., Gedallovich, J., Shah, J. C., & Baker, M. C. (2025) · BMC Rheumatology · doi:10.1186/s41927-025-00548-1 · Cited by 2
Zhorzholiani, P., Bokhua, Z., Kepuladze, S., & Burkadze, G. (2025) · GEORGIAN SCIENTISTS · doi:10.52340/gs.2025.07.01.06 · Cited by 1
New anticancer medicines approved by the EMA in 2024
Bege, M., & Borbás, A. (2025) · De Remediis · doi:10.71116/ksgqxh79 · Cited by 1
Li, N., Li, X., Xu, Y., Zhang, Y., Si, Y., Zhao, H., & Ren, Q. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118895 · Cited by 1
Zhang, T., Nan, Z., Guo, S., Yang, S., Li, L., Zhang, Y., Yan, X., Hu, Z., & Zhao, C. (2026) · Scientific Reports · doi:10.1038/s41598-026-52487-7 · Cited by 1
Metadata
- Authors
- Arafat Hossain, M.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2024-12
- Volume
- 143
- Issue
- Pt 2
- Pages
- 113365
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W4403679157
- Cited by
- 178
- References
- 626
- FWCI
- 27.32
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.